Search results
Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication
Zacks via Yahoo Finance· 2 years agoJazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy...
Natural Treatment Options for Epilepsy
Verywell Health via Yahoo News· 12 months agoEpilepsy is a brain disorder that causes seizures. Talking to your healthcare provider before trying any epilepsy treatment is important, whether it’s a...
Epilepsy Medication: Types and Available Options
Verywell Health via Yahoo News· 8 months agoMedications that treat epilepsy vary based on the type of seizure disorder. There are two main types of epilepsy drugs: narrow-spectrum anti-epileptic...
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
Zacks via Yahoo Finance· 3 months agoJazz Pharmaceuticals JAZZ reported adjusted earnings of $5.02 per share in fourth-quarter 2023,...
Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have...
3 Top Pot Stocks to Watch in September
Motley Fool· 2 years agoCannabis investors who have heard the siren call of how much growth is expected in the industry may be getting a little frustrated this year, with the...
Japan unit of Britain's Jazz Pharma starts phase III trial of cannabis drug
Reuters via Yahoo Finance· 1 year agoThe Japanese unit of Britain's Jazz Pharmaceuticals PLC said on Thursday it had started a phase III trial of a cannabis-based drug for epilepsy. The trial follows a recommendation by a health ...
These parents fought to legalize CBD in Utah a decade ago. Did it help their epileptic children?
Deseret News via Yahoo News· 10 months agoA decade ago, some self-described “Molly Mormon” moms persuaded Utah lawmakers to let them use CBD...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript February 28, 2024 Jazz...
Jazz Pharmaceuticals PLC (JAZZ) Reports Strong Revenue Growth and Robust Pipeline Progress
GuruFocus.com via Yahoo Finance· 3 months agoTotal Revenues: $3.8 billion in 2023, with a 27% year-over-year increase from key growth drivers....
